Filter 228 Results

Modality
Application
Technology
Service
Content Type

Achieving Bioavailability Enhancement for Poorly Soluble Compounds: Streamlining Technology Selection

A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. In this on-demand webinar, hear about some of the most common bioavailability-enhancing technologies for poorly soluble compounds and a strategic framework for identifying and selecting the appropriate technology. A case study is presented.
Authors: Aaron Stewart
Publish Date: 30-Apr-2021

Achieving Bioavailability Enhancement for Poorly Soluble Compounds: Streamlining Technology Selection

A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. A case study is also presented in these webinar slides.
Authors: Aaron Stewart
Publish Date: 30-Apr-2021

Selecting the Right Technology for Oral Delivery of Low Solubility Molecules

The right oral delivery technology is dictated by drug physicochemical properties and target product profile. Technology selection and formulation design begins during solid form selection and preformulation. View our downloadable presentation and read case studies covering amorphous dispersions, nanocrystals, and lipid formulations.
Authors: Michael Grass
Publish Date: 20-Apr-2021

Selecting the Right Technology for Oral Delivery of Low Solubility Molecules

The right oral delivery technology is dictated by drug physicochemical properties and target product profile. Technology selection and formulation design begins during solid form selection and preformulation. Case studies from this on-demand presentation will cover formulations including amorphous dispersions, nanocrystals, and lipid formulations.
Authors: Michael Grass
Publish Date: 20-Apr-2021

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

This peer-reviewed publication highlights how amorphous solid dispersion dosage forms can improve patient compliance and efficacy of acalabrutinib and other weakly basic drugs that have pH-dependent absorption.
Publish Date: 20-Apr-2021

SimpliFiH® Solutions for Accelerated Pharmaceutical Development

With the pharmaceutical industry’s focus on accelerating all aspects of drug discovery and development, it is crucial to reduce the time from initial product concept to first-in-human clinical completion. Numerous factors can slow this process, but challenges can be overcome by aligning with a single, integrated Contract Development and Manufacturing Organization (CDMO) to reduce the time, complexity, risks, and costs associated with engaging multiple partners. To learn more, read our executive summary.
Publish Date: 19-Apr-2021

Webinar on Scalable suspension LVV production platforms for cell and gene therapy_CGT

Lentiviral vector is the predominant delivery vehicle used for introducing genetic modifications into cell therapies such as CAR-T and HSC gene therapies. Fueled by recent clinical successes and landmark approvals, this field continues to experience unprecedented pipeline growth and investor interest along with a concommitant growth in demand for Lenti viral vector manufacturing. Traditional processes for Lenti manufacturing rely on lab-scale, open, manual processes that are predominantly adherent-based and difficult to scale up. There is a pressing need for industrialization of these production methods to meet market demand and to ensure successful commercialization of cell and gene therapies. In this Webinar, Lonza CGT will focus on how we are tackling these challenges through development of an optimized, scalable suspension-based Lenti production platform using our proprietary HEK293T clonal cell line. We will also highlight some of the innovation and process improvements steps that have been implemented to support trailblazers of CGT to generate commercially viable therapies to from concept to patient.
Publish Date: 14-Apr-2021

Predicting, Avoiding and Mitigating Risk of Failure when Developing Biotherapeutics

Developability issues can contribute to the high attrition rate of potential biotherapeutic candidates. Such issues can arise from manufacturability risks due to post-translational modifications and aggregation, and immunogenicity risks due to the presence of T-cell epitopes. There is a critical need to de-risk the candidates as early as possible during development to improve their success rate. The presentation will describe how in silico and in vitro tools can be employed to highlight, predict and mitigate manufacturability, expression and immunogenicity risks, thereby reducing the risk of failure for the development of biotherapeutics. 
Publish Date: 09-Apr-2021

Quality From The Start: Preparing For A Successful Transition From Late Stage Discovery To Clinic

During this webinar, we discuss and explore how advancing an innovative drug from late stage discovery into the clinic is the most-critical step in drug product development. While drug developers would like to gain as much information on the product as early as possible, the scientific focus is on the drug design for optimal efficacy and high safety profile at this stage. This is when key decisions are made that have a long-term impact and pave the way for clinical and commercial manufacturing as well as the future supply chain. In this early phase, it is less about speed,and more important to focus on quality from the start.
Authors: Tristan Wilkins
Publish Date: 09-Apr-2021

Streamlining High Throughput Impurity Analysis in Process Development

In the biopharma industry, there currently is a need to increase production capacity to meet the analytical demands of process development and characterization, which investigate multiple parameters. In this GEN webinar, we will hear about some of the latest advances in high-throughput analytics, with particular attention on the High-Throughput Impurity Detection platform for automated impurity quantitation from Lonza. Additionally, we will hear about some of the unique automation challenges that face biomanufacturers, as well as some novel chemistry and vendor selection methodologies that have been designed to save researchers valuable time and money.
Authors: Hannah Gibbons
Publish Date: 09-Apr-2021